Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS) by Palmerini, Emmanuela et al.
1Scientific RepoRtS |        (2020) 10:10853  | https://doi.org/10.1038/s41598-020-66579-5
www.nature.com/scientificreports
Angiosarcoma of bone: a 
retrospective study of the european 
Musculoskeletal oncology Society 
(eMSoS)
emanuela palmerini  1 ✉, Andreas Leithner2, Reinhard Windhager  3, Georg Gosheger4, 
Kjetil Boye  5, Minna Laitinen  6, Jendrik Hardes4, frank traub  7, paul Jutte  8, 
Madeleine Willegger3, Jose’ casanova9, elisabetta Setola1, Alberto Righi1, piero picci1, 
Davide Maria Donati  1 & Stefano ferrari1
Angiosarcoma of bone (B-AS) is a rare malignant tumor of vascular origin. the aim of this retrospective 
study is to report on treatments and prognosis. Data were collected from the EMSOS website. 80 
patients in 9 centers included: 51 male/29 female; median age 54 years (range 17 to 92); 56% with 
localized disease, 44% metastatic. Primary tumor surgery: 76% (30% amputation, 26% intralesional 
margins); radiotherapy (RT): 41%; chemotherapy (CT): 47% (56% in metastatic, 41% in localized cases). 
With a median follow-up of 31 months (range 40 to 309), 5-year overall survival (OS) was 27% (95%CI 
16–30): 41% (95%CI 25–56) for localized patients, and 8% (95%CI 0–20) for metastatic (p = 0.002). In 
metastatic patients, 1 year OS was significantly influenced by chemotherapy response: 67% (95CI% 
29–100) for those who responded or had stable disease (n = 7), and 18% (95CI% 0–41) for patients 
with progressive disease (n = 11), p 0.002. The surgical complete remission (SCR) status was pivotal 
in localized patients (5-year OS 45% for SCR, 17% no SCR, p = 0.03); also 5-year OS was significantly 
influenced by age and site of the tumor. After multivariate analysis, the addition of radiotherapy to 
surgery significantly influenced the disease-free survival (DFS) rate, whereas the use of chemotherapy 
lost the significance showed at the univariate analysis. Overall, patients with metastatic B-AS have a 
dismal prognosis, with a prolonged survival in case with a response to chemotherapy. experimental 
trials with more active systemic treatment regimens are needed. in patients with localized disease, the 
patient’s age and site of the tumor are prognostic factors and any effort must be made to achieve an 
SCR status. No definitive conclusions can be drawn from our data on the use of adjuvant chemotherapy, 
while the use of adjuvant radiotherapy might improve DSf in patients surgically free of disease.
Angiosarcoma of bone (B-AS) is exceedingly rare, accounting for less than 1% of all primary bone sarcomas, with 
the highest incidence between 50 and 70 years of age1,4. The diagnosis of B-AS is challenging and represents the 
malignant end of the spectrum of CD31/ERG positive vascular tumors, including hemangiomas, hemangioen-
dotheliomas, well-differentiated and poorly differentiated angiosarcomas1–3 (Fig. 1). The disease might present 
as unifocal or with multifocal bone lesions, and it is usually associated with a poor prognosis1–6. Given the rarity 
of B-AS, only scant information can be found in the literature, mostly reported in form of small series and case 
reports. No specific treatment guidelines or position papers are available, so the treatment of choice is based on 
data from other types of bone and soft tissue sarcomas1,3–7. The role of chemotherapy and prognostic factors for 
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these patients is still unclear8,9. Published larger series results are difficult to interpret due to inclusion of both 
low and high-grade vascular tumors of bone10–12, soft tissue and B-AS13, or lack of information on treatments3,14.
A European retrospective study has been carried out. The European Musculoskeletal Oncology Society 
(EMSOS) supported the study that was open to the members of the society. Clinical characteristics, treatment 
modalities and outcome were collected and the final analysis of the data is here reported.
patient and Methods
patient selection. Through the EMSOS website the study protocol and the data set for the collection of the 
information of interest were made available to the EMSOS members. Study protocol was approved by the Ethics 
Committee of the IRCCS Istituto Ortopedico Rizzoli (coordinating center for the study), and informed consent 
and privacy agreements were obtained from all participants and/or their legal guardians.
All methods were performed in accordance with relevant guidelines and regulations.
Patients with histological diagnosis of B-AS were included into the study. Each center reviewed the patholog-
ical samples for the purpose of the study and confirmed the diagnosis. To confirm the morphological diagnosis, 
the standard immunohistochemical (IHC) panel consists of the following markers: ERG and CD31 (endothelial 
markers), cytokeratin AE1, and CAMTA1 and TFE3 (to rule out epithelioid hemangioendothelioma)15.
The data collection included demography, clinical presentation, type of treatment (local and systemic) and 
outcome. In cases with full pathology report available IHC markers were also reported.
Depending on the disease presentation, patients were classified as localized or metastatic (any site). The pri-
mary tumor locations were grouped as follows: extremity, pelvis/sacrum and central (all axial lesions excluding 
pelvis/sacrum). Surgical margins were considered adequate if wide or radical, and inadequate when intralesional, 
marginal or contaminated16. A surgical complete remission (SCR) was defined as the surgical removal of the pri-
mary tumor and, for metastatic patients, of all sites of metastatic disease. The response to chemotherapy (when 
available) in metastatic patients was assessed according to RECIST 1.117.
Anonymized data has been sent to the study-referral center (IRCCS Istituto Ortopedico Rizzoli, Bologna, 
Italy) that performed the statistical analysis. Descriptive statistics were used to summarize population characteris-
tics. Comparisons between groups were made by chi-square analysis or using Fisher’s exact test when appropriate.
Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier analysis. OS was 
calculated from the date of diagnosis to death (any cause) or to last follow-up.
DFS was calculated from date of SCR to the occurrence of local or distant recurrence, death of any cause or 
last follow up.
OS and DFS were analyzed with respect to potentially prognostic variables including gender, age (≤ 50 years,> 
50 years), stage (localized vs. metastatic), administration of chemotherapy and/or radiotherapy, and achievement 
of a SCR status. Multivariate analysis including significant and clinically relevant variables was performed.
Results
Demographic. Nine centers (IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Department of Orthopaedics 
and Trauma, Medical University of Graz, Austria; Medical University of Vienna, Department of Orthopaedic 
Surgery, Vienna, Austria; Westfalian Wilhelms University, University Hospital Muenster, Department of 
Orthopaedics and Tumor Orthopaedics, Muenster, Germany; Department of Oncology and Department of 
Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway; Bone Tumour Unit, Department of Orthopaedics 
and Traumatology Helsinki University Hospital, Helsinki, Finland; Department of Orthopaedic Surgery 
Eberhard Karls University, Tuebingen, Germany; Department of Orthopaedic Surgery, University Medical Center 
Groningen, University of Groningen, the Netherlands; Orthopedic University Hospital University of Coimbra, 
Coimbra, Portugal) with a specific expertise in sarcomas from 7 European countries participated in the study.
Data from 89 patients treated between 1976 and 2017 were collected. Six patients were excluded due to incor-
rect diagnosis and three patients had missing data; 80 patients were included in the present analysis.
The clinical characteristics of the patients are reported in Table 1, with IHC markers in a subset of the cases 
summarized in Table 2. The study population comprised patients with a wide range of age with a prevalence of 
male gender. Femur and pelvis were the most frequent primary tumor locations. The incidence of patients with 
metastatic disease at diagnosis was 44%. Multivisceral metastases were identified in 16 patients: lung metastases 
Figure 1. Bone angiosarcoma microscopy: irregular and haphazard blood-filled cavities rimmed by highly 
malignant atypical cells diffusely permeating the host trabeculae at hematoxilin and eosin staining (panel a), 
with a strong CD31 (panel b) and ERG (panel c) positivity.
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in seven patients, splenic in one patient, lymph node in one with eight patients had multifocal bone locations, 
and the site was not specified in two patients. There were no differences in clinical presentation according to age, 
sex and site between localized and metastatic patients (Table 1). The IHC panel confirms that both presence of 
endothelial markers (CD31 and ERG) and lack of TFE3 and CAMTA have high specificity and sensibility for the 
diagnosis of angiosarcoma of bone, with focal expression of cytokeratin AE1/AE3 in 9% of the cases (Table 2, 
Fig. 1).
Local treatment. Surgery. Sixty-one patients (76%) out of 80 underwent surgery of the primary lesion: 
87% (39 of 45) in patients with localized disease and 36% (22 of 35) in cases with metastatic disease. Eighteen 
(30%) patients had an amputation, while 43 (70%) patients underwent other surgical procedures.
Surgical margins, available in 38 cases, were adequate in 24 (63%), and inadequate in 14 (37%) patients (10 
intralesional and four marginal). Focusing on localized patients, surgical margins were reported in 26 patients 
and were wide in 19, marginal in two and intralesional in five patients.
Overall, data on surgical complete remission (SCR) were available for 76 patients. The rate of SCR was 47% 
(one of the 35 patients presenting with metastases achieved SCR, and 35 of 45 patients with localized disease).
Radiotherapy. Data on the use of radiotherapy were available in 77 patients: 32 received radiotherapy: two 
(6%) patients, both presenting with metastases, received radiotherapy as definitive local treatment, eight (25%) 
patients with localized disease underwent adjuvant radiotherapy after surgery, and in the remaining 22 (69%) 
patients low dose (about 30 Gy) radiotherapy was administered with palliative intent.
chemotherapy. Data on chemotherapy use were available in 77 patients. Chemotherapy was administered 
to 36 (47%) patients, 18 had localized disease and 18 had synchronous metastases.
Adjuvant regimens included osteosarcoma-like treatment (doxorubicin, methotrexate, cisplatin and ifosfa-
mide) in six patients (33%), doxorubicin ± ifosfamide in four (22%), three (17%) and two (11%) patients respec-
tively underwent paclitaxel and gemcitabine, while the type of treatment was not reported in three cases. For 
metastatic patients chemotherapy regimens adopted in first line and RECIST responses are detailed in Table 3.
All
Metastatic 35(44)
n (%)
Localized 45(56)
n (%) p
Sex
0.7F 29 (36) 12 (34) 17 (38)
M 51 (64) 23 (66) 28 (62)
Site of primary
0.4
Extremity 45 (56) 18 (52) 27 (60)
Central 16 (20) 6 (17) 10 (22)
Pelvis + Sacrum 19 (24) 11 (31) 8 (18)
Age
0.9
median (min-max) 54 (17–92) 58 (23–92) 53 (17–74)
≤ 50 yrs 28 (35) 12 (34) 16 (36)
> 50 yrs 52 (65) 23 (66) 29 (64)
Pattern of metastases
na
Multiple sites 16 (46) 16 (46) na
Bone (multifocal) 8 (23) 8 (23) na
Lungs 7 (20) 7 (20) na
Nodes 1 (3) 1 (3)
Spleen 1 (3) 1 (3)
Unknown 2 (5) 2 (5)
Table 1. Clinical Characteristics. na = not applicable.
Antibody
Percent of positive tumors
n %
CD31 47 100
ERG 47 100
Cytokeratin AE1 4 9
TFE3 47 0
CAMTA1 47 0
Table 2. Immunohistochemical angiosarcoma tumor markers expression.
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outcome. With a median follow-up of 31 months (from 4 to 309 months) 54 (68%) patients were dead of 
disease, 23 (16%) were alive with no evidence of disease, 10 (12%) were alive with disease and 3 were dead of other 
causes (thyroid cancer, colon cancer, not specified in one case).
The 5-year OS was 27% (95%CI 16–30), 41% (95%CI 25–56) for localized and 8% (95%CI 0–20) for metastatic 
patients (p = 0.002) (Fig. 2).
patients with localized disease. The 5-year OS was 45% (95%CI 28–62) for 39/45 patients with localized 
disease who underwent surgery and achieved a SCR status and 17% (95%CI 0–46) for 6/45 patients not surgically 
treated (p < 0.001).
Limiting the analysis to 26 patients with localized lesions and available information on quality of margins, 
5-year OS was 42% for patients with wide margins. None of the patients with intralesional margins were alive at 5 
years and only one of the two cases with marginal margins was alive at the 5-year mark.
In six patients with localised disease who did not undergo surgery, the tumor was mainly located in the axial 
skeleton (four pelvis/sacrum, one spine, and one femur). In five of the patients exclusive radiotherapy was per-
formed. All patients with no surgery have died with a median time to death of nine months (range 3–27 months), 
while one patient undergoing gemcitabine after radiation therapy on the primary tumor was alive with disease 
after 29 months of follow-up.
The 5-year DFS was 37% (95% CI 19–56), better in patients ≤ 50 years old), and in those who received adju-
vant chemotherapy (Table 4; Fig. 3). Four of the five patients (80%) with localized disease and SCR who received 
adjuvant radiotherapy were free of disease at the 5-year timepoint, compared with 34% in those who did not.
The multivariate analysis demonstrated that patients who were less than 50 years of age and use of radiother-
apy were associated with improved DFS in patients with localized tumors able to achieve SCR (Table 5).
After SCR, a better OS was reported in younger patients (≤ 50 years old) and in those patients with tumors 
located in the extremities, none confirmed at multivariate analysis (Tables 6, 7).
patients with synchronous metastases. Of the 35 patients with synchronous metastases, 29 have died, 
with a median time to death of six months (range 1–49 months), six patients were alive with disease, with a 
median time of observation of 22 months (range 8–106 months). One of them was 39-year old male with a B-AS 
localized in the pelvis and multiple metastases. He underwent chemotherapy with doxorubicin and ifosfamide, 
radiotherapy on primary tumor, lung and bone metastases, and several surgical treatments in the ileum and in the 
hip for pathological fractures. He was still alive 9 years after diagnosis.
The 1- year OS was 22% (95% CI 8–37) and the 5-years OS was 8% (95% CI 0–20). Only one patient with 
angiosarcoma of the femur and lung metastases achieved a SCR status. After surgical resection of the primary 
Regimen n° (%) of pts
Best Result (RECIST 1.1)
PR SD PD
Doxorubicin- Ifosfamide 8 (44) 2 6
Osteosarcoma-like 4 (22) 1 3
Paclitaxel 3 (17) 1 2
Gemcitabine 2 (11) 2
Caelix 1 (6) 1
Table 3. Best response in 18 patients with metastatic disease receiving chemotherapy (RECIST 1.1). *Standard 
doxorubicin or pegylated liposomal doxorubicin.
Figure 2. Five-year overall survival (OS) of 80 patients with bone angiosarcoma by stage at presentation.
5Scientific RepoRtS |        (2020) 10:10853  | https://doi.org/10.1038/s41598-020-66579-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
tumor and metastases, he underwent adjuvant radiotherapy and systemic chemotherapy treatment. He died of 
disease (brain metastases) 12 months after diagnosis.
The OS was not influenced by the use of chemotherapy: the 2-year OS was 15% [95% CI 3–43] in 18 patients 
who underwent chemotherapy and 17% [95%CI 0–38] in those (n = 14) who did not. A partial response (PR) was 
documented in one patient who received paclitaxel, while stable disease (SD) was reported in five patients (two 
Variable Pts n° 5-year DFS 95% CI
pAll 35 37 19–56
Age
≤ 50 yrs 12 74 49–100
0.0007
> 50 yrs 23 22 4–41
Sex
M 23 43 23–64
0.9
F 12 29 0–61
Site
extremity 25 46 26–66
0.1central 6 33 0–71
pelvis+sacrum 4 25 0–67
Chemotherapy
Yes 14 49 19–78
0.04
No 21 33 13–53
Radiotherapy*
Yes 5 80 45–100
0.2
No 29 34 16–53
Table 4. Univariate analysis for disease-free survival (DFS) in localised and surgically treated patients and 
complete remission (SCR). M: male; F: Female; DFS: disease-free survival. *Radiotherapy information was 
available for 34 patients.
Figure 3. Five-year diseases-free survival (DFS) in patients with localized disease and who achieved a surgical 
complete remission (SCR), according to the use of adjuvant chemotherapy.
Variable RR 95% CI p
Age
> 50 yrs 1
0.01
≤ 50 yrs 0.17 0.04–0.68
Site
pelvis+sacrum 1
0.96
0.21central 1.04 0.16–6.67
extremity 0.43 0.11–1.63
Chemotherapy
Yes 1
0.18
No 1.97 0.73–5.36
Radiotherapy*
Yes 1
0.04
No 6.4 1.08–37.97
Table 5. Multivariate analysis for disease-free survival (DFS) in localised and surgically treated patients 
and complete remission (SCR). RR: relative risk; CI: confidence interval; M: male; F: Female. *Radiotherapy 
information was available for 34 patients.
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after gemcitabine, two after doxorubicin and ifosfamide and one after a osteosarcoma-like regimen) (Table 3). 
The 1-year OS was 67% (95CI% 29–100) for those who responded or had stable disease (n = 7), and 18% (95CI% 
0–41) for patients with progressive disease (n = 11), p 0.002. Metastatic pattern and age did not influence the 
survival rates.
Discussion
This study, carried out in the framework of the EMSOS network, confirms the rarity and the aggressive behaviour 
of primary B-AS. The scarcity of the patient population represents a treatment challenge, even in referral centers.
Most of the patients were metastatic at diagnosis (44%), and this incidence is twice that reported in other bone 
sarcomas18. Furthermore, half of the patients presented with metastases in multiple sites (only 9% of the patient 
had lung only metastases).
Overall the prognosis of B-AS is very poor, with a 5-year survival rate for metastatic patients of only 8%, 
and also poor results also for patients with localized disease unable to achieve a SCR status (5-year OS 17%). 
Still, it is important to underscore that for a small subgroup of patients (12 patients with localized angiosarcoma 
younger than 50 years of age) the 5-year OS was 68%, not much different from high-grade bone tumors, such as 
osteosarcoma.
This heterogeneity in clinical behaviour might be related to the high genetic variability described in angiosar-
comas, with several genes abnormalities identified in B-AS patients such as CIC, PLCG1, KDR and MYC (14–15).
The main factors significantly related to the survival were the stage, patient age and the site of the tumor.
Overall, the local treatment of these tumors reflects their aggressiveness: In about 1/4 of patients surgery of 
the primary tumor was not feasible, and when surgery was performed, in 30% of patients it was an amputation.
Our study confirms the importance of surgery in patients with localized disease, showing a survival benefit in 
those patients who achieved a SCR status. Achieving adequate surgical margins is important, as no patients with 
an intralesional resection survived. Therefore a surgical approach should only be considered if it is likely achieve 
adequate surgical margins.”
In metastatic patients, it is questionable to adopt aggressive surgical procedures since the low, if any, possibil-
ities of achieving a surgical remission. Furthermore, it is important to note that the only one metastatic patient 
who was rendered free of disease, soon relapsed with distant metastases.
Variable Pts n° 5-year 0S 95% CI p
All 39 45 28–62
Age
≤ 50 yrs 13 68 41–94
0.02
> 50 yrs 26 34 13–55
Sex
M 26 57 26–77
0.3
F 13 25 0–53
Site
extremity 26 50 29–72
0.008central 9 58 22–95
pelvis+sacrum 4 0
Chemotherapy*
yes 16 49 19–78
0.4
no 21 42 20–63
Radiotherapy**
yes 8 71 38–100
0.4
no 30 40 20–60
Table 6. Univariate analysis for overall survival (OS) in localised and surgically treated patients and complete 
remission (SCR). OS: overall survival; CI: confidence interval; M: male; F: Female. *Chemotherapy information 
was available for 37 patients; **Radiotherapy information was available for 38 patients.
Variable RR 95% CI p
Age
> 50 yrs 1
0.08
≤ 50 yrs 0.35 0.1–1.1
Site
pelvis+sacrum 1
0.2
0.04central 0.3 0.1–1.9
extremity 0.25 0.1–0.9
Chemotherapy*
yes 1
0.9
no 0.9 0.3–2.5
Radiotherapy
Yes 1
0.5
No 1.5 0.4–6.2
Table 7. Multivariate analysis for overall survival (OS) in localised and surgically treated patients and complete 
remission (SCR). RR: relative risk; CI: confidence interval. *Chemotherapy information was available for 37 
patients; **Radiotherapy information was available for 38 patients.
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No definitive conclusions can be drawn regarding the role of chemotherapy on B-AS. The data collected in the 
present analysis indicates that chemotherapy might be of assistance in B-AS. In metastatic patients overall the use 
of chemotherapy did not offer a better survival rate, but it is relevant to note that a significantly better 1-year OS 
was observed in the few patients who had a disease stabilization after chemotherapy. A significantly better DFS 
was reported, in localized patients who achieved a complete SCR and received adjuvant chemotherapy. This was 
not confirmed after multivariate analysis. On the other hands, this is a small sample size and these results should 
be taken with some caution due to the small number of patients considered.
Overall, the data reported both on adjuvant chemotherapy advantage in patients with localized B-AS achiev-
ing a SCR status and the evidence of tumor shrinkage and/or disease stabilization with taxol and gemcitabine in 
some patients suggests that chemotherapy has some activity in B-AS; nonetheless at present no recommendation 
on superiority of a specific chemotherapy regimen can be provided and more effective systemic treatment are 
needed.
Radiotherapy was mainly used with palliative intent in metastatic patients and in localized patients when 
surgery was not feasible. Interestingly, 4 of the 5 patients with localized disease and SCR who received adjuvant 
radiotherapy were free of the disease after 5 years. With the limitation of the small number of patients, the mul-
tivariate analysis does show an advantage from adjuvant radiotherapy in B-AS with SCR. It will be important in 
future studies to address whether the current radiotherapy techniques, including protontherapy, or tomotherapy 
can offer some advantages in terms of tumor control.
Multivariate analysis has a number of limitations owing to the small number of patients included in this study. 
Nonetheless, it confirms a better prognosis in terms of DFS for patients younger than 50 years old and it shows 
that radiotherapy might reduce the risk of relapse for patients with localised B-AS achieving surgical complete 
remission.
conclusions
B-AS is a rare and aggressive tumor with heterogeneous behaviour. Overall, patients with metastatic B-AS have 
a dismal prognosis, with prolonged survival in cases that respond to chemotherapy. Experimental trials focusing 
on more active systemic treatment regimens are needed.
In patients with localized disease, the patient’s age and site of the tumor are prognostic factors and any effort 
must be made to achieve a SCR status. No definitive conclusions can be drawn from our data on the use of adju-
vant chemotherapy while the use of adjuvant radiotherapy might improve DSF in localized patients surgically 
free of disease.
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